杨凯婷

Cooley advised biotechnology company Keymed Biosciences on its HK$3.1 billion (US$400 million) initial public offering on the Hong Kong Stock Exchange. Partners Yiming Liu, Michael Yu and Will Cai led the Cooley team advising Keymed Biosciences on its public debut, which also included Yiying Wang, Xiaoyu Xu, Kaiting Yang, Henry Wang, Bridget Wang and Iris Yang.

Cooley advised Asymchem Laboratories, a contract development manufacturing organization (CDMO) serving the global pharmaceutical industry, on its HK$7.15 billion (US$916 million) initial public offering – marking the largest healthcare IPO in Hong Kong this year – of 18,415,400 H shares, which now trade on the Hong Kong Stock Exchange. Partners Yiming Liu and Michael Yu led the Cooley team advising Asymchem.

Cooley advised the joint sponsors and underwriters on ecommerce company Huitongda’s HK$2.2 billion (US$285 million) initial public offering of 51,606,200 H shares on the Hong Kong Stock Exchange, subject to the exercise of the underwriters’ option to purchase an additional 7,740,900 H shares. Partners Michael Yu and Will Cai led the Cooley team advising the joint sponsors and underwriters.